Understanding Heart Failure With Preserved Ejection Fraction
Official title: Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
Run by Manchester University NHS Foundation Trust · NCT05383287 · Data updated 2026-11-12
This study looks at people with heart failure that has preserved ejection fraction to understand what causes it and find better tests and treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1250 (estimated) |
| Sponsor | Manchester University NHS Foundation Trust Government |
| Locations | 1 site (Manchester) |
| Status | Recruiting |
| Started | August 12, 2022 |
| Main results expected | October 2029 |
| Study ends | October 2029 |
| Registry record updated | October 1, 2025 |
| Trial ID | NCT05383287 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults attending the HFpEF clinic at Manchester University NHS Foundation Trust.
✕Probably not a fit
Patients under 18 years old, those who are imprisoned, or those unable to provide informed consent in English may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on heart failure with preserved ejection fraction (HFpEF), a condition where the heart struggles to pump blood effectively. It aims to identify the underlying causes of HFpEF, explore new tests and treatments, and assess the life expectancy of affected individuals. By collecting data from patients attending a specialized HFpEF clinic, the study seeks to characterize different phenotypes of HFpEF and their clinical outcomes, ultimately guiding future research and personalized care strategies.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and targeted treatments for patients with HFpEF.
How similar studies have gone: While HFpEF has been a challenging area with limited treatment success, the approach of characterizing patient phenotypes is gaining traction and has shown promise in other studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients attending the HFpEF clinic at MFT. Exclusion Criteria: * Age \< 18 years * Imprisonment * Inability to provide full written or verbal informed consent in English
Where it's running
-
Manchester University NHS Foundation trust
Manchester, United Kingdom Recruiting
Study contacts
- Principal investigator: Chris Miller, MBChB, MRCP — Manchester University NHS FT
- Study coordinator: Fardad Soltani, MBChB, MRCP
- Email: fardad.soltani@mft.nhs.uk
- Phone: 0161 291 3223
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease
This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.
-
Optimised Cardio-Renal Care for CKD and heart disease
This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.
-
Resmetirom for MASH with HFpEF in adults
This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.
-
Elecoglipron vs placebo for adults with HFpEF or HFmrEF
This Phase 3 study tests whether elecoglipron helps people with HFpEF or HFmrEF who are on dapagliflozin and standard care.
-
Iron infusion and MRI to study inflammation in HFpEF
A small early-phase study tests whether an iron infusion affects heart inflammation in people with HFpEF, using MRI measures before and after treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.